These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32333865)

  • 1. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
    Kalra S; Kalhan A; Berard L
    Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
    Iwamoto H; Kimura T; Fushimi Y; Iwamoto M; Tatsumi F; Sanada J; Iwamoto Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Oct; 26(10):4366-4374. PubMed ID: 39039725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell SA
    Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
    [No Abstract]   [Full Text] [Related]  

  • 9. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
    Semenya AM; Wilson SA
    Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
    [No Abstract]   [Full Text] [Related]  

  • 12. What the SELECT trial of semaglutide means for clinicians.
    Sattar N; Lee MMY; McGuire DK
    Nat Med; 2024 Jul; 30(7):1830-1831. PubMed ID: 38796654
    [No Abstract]   [Full Text] [Related]  

  • 13. The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.
    Dichtel LE
    Hepatology; 2021 Oct; 74(4):2290-2292. PubMed ID: 33960005
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice].
    Karásek D
    Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
    Giugliano D; Esposito K; De Nicola L
    Diabetes Obes Metab; 2024 Nov; 26(11):4813-4815. PubMed ID: 39219442
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
    N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral semaglutide (Rybelsus) for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
    [No Abstract]   [Full Text] [Related]  

  • 20. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
    Emoto M; Terauchi Y; Ozeki A; Oura T; Takeuchi M; Imaoka T
    Endocr J; 2015; 62(12):1101-14. PubMed ID: 26477324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.